Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
OrbiMed Advisors LLC, a prominent investment firm, has reported a significant sale of shares in Compass Therapeutics, Inc. (NASDAQ:CMPX), a company currently valued at $228 million. According to a recent SEC filing, OrbiMed Advisors sold 3,571,428 shares of Compass Therapeutics at a price of $1.59 per share, totaling approximately $5.68 million. The stock has since rallied, trading at $1.70 and showing strong momentum with a 16% gain over the past week. This transaction leaves OrbiMed with no remaining shares of this specific holding. The sale was executed on April 9, 2025, and the filing was submitted on April 11, 2025. While the company maintains a strong balance sheet with a current ratio of 14.96 and minimal debt, InvestingPro analysis indicates rapid cash burn as a key concern. Analysts remain optimistic, with price targets ranging from $6 to $32, suggesting significant potential upside. For more detailed insights and additional ProTips on CMPX, explore InvestingPro.
In other recent news, Compass Therapeutics announced promising results from its COMPANION-002 Phase 2/3 trial, which evaluated the combination of tovecimig and paclitaxel in treating advanced biliary tract cancer. The therapy demonstrated a statistically significant improvement in overall response rate compared to paclitaxel alone, showing a notable increase from 5.3% to 17.1%. Meanwhile, Leerink Partners upgraded Compass Therapeutics’ stock rating from Market Perform to Outperform, raising the price target to $6, driven by a positive outlook on the company’s clinical programs. Stifel analysts maintained their Buy rating with a $10 price target, expressing optimism about the upcoming release of topline data from the COMPANION-002 trial. Piper Sandler also initiated coverage with an Overweight rating and a $12 price target, citing confidence in the company’s lead program, tovecimeg. Analysts from these firms highlight the upcoming trial data as a significant milestone for Compass Therapeutics, potentially influencing its valuation and market position. The company is preparing to discuss the trial results with regulatory authorities, marking an important step in its development strategy. These developments reflect a period of active engagement and anticipation within the investment community regarding Compass Therapeutics’ future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.